Voyager Therapeutics, Inc. (NASDAQ:VYGR) Shares Purchased by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. boosted its stake in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 64.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 10,489 shares of the company’s stock after buying an additional 4,098 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in Voyager Therapeutics were worth $61,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Great Point Partners LLC acquired a new stake in Voyager Therapeutics in the second quarter valued at $12,668,000. Farallon Capital Management LLC grew its stake in Voyager Therapeutics by 77.4% in the 1st quarter. Farallon Capital Management LLC now owns 2,292,000 shares of the company’s stock valued at $21,339,000 after acquiring an additional 1,000,000 shares during the last quarter. Vanguard Group Inc. raised its position in Voyager Therapeutics by 27.8% during the first quarter. Vanguard Group Inc. now owns 3,231,698 shares of the company’s stock worth $30,087,000 after acquiring an additional 702,030 shares during the last quarter. Armistice Capital LLC lifted its holdings in shares of Voyager Therapeutics by 11.3% in the second quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock valued at $41,132,000 after purchasing an additional 528,000 shares in the last quarter. Finally, American Century Companies Inc. grew its position in shares of Voyager Therapeutics by 32.4% in the second quarter. American Century Companies Inc. now owns 1,019,332 shares of the company’s stock valued at $8,063,000 after purchasing an additional 249,659 shares during the last quarter. 48.03% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $5.82, for a total transaction of $34,914.18. Following the completion of the sale, the insider now owns 86,001 shares of the company’s stock, valued at approximately $500,525.82. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 4.53% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently issued reports on VYGR shares. Leerink Partnrs upgraded Voyager Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 16th. Leerink Partners started coverage on Voyager Therapeutics in a research note on Wednesday, October 16th. They set an “outperform” rating and a $15.00 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of Voyager Therapeutics in a research note on Thursday, October 24th. StockNews.com cut shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, October 25th. Finally, Wedbush cut their price objective on shares of Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating for the company in a research report on Wednesday, August 7th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $17.43.

Voyager Therapeutics Stock Performance

Shares of VYGR stock opened at $6.83 on Friday. The firm has a market capitalization of $371.51 million, a price-to-earnings ratio of -136.60 and a beta of 0.91. Voyager Therapeutics, Inc. has a one year low of $5.71 and a one year high of $11.72. The company has a 50 day moving average price of $6.56 and a 200 day moving average price of $7.58.

Voyager Therapeutics (NASDAQ:VYGR) last issued its earnings results on Tuesday, August 6th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.20. Voyager Therapeutics had a return on equity of 3.31% and a net margin of 6.28%. The business had revenue of $29.58 million for the quarter, compared to analyst estimates of $11.52 million. During the same period last year, the company posted ($0.51) EPS. As a group, equities analysts forecast that Voyager Therapeutics, Inc. will post -1.27 EPS for the current fiscal year.

Voyager Therapeutics Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.